Brief: Plus Therapeutics Presents Positive Respect-LM Trial Results Of Reyobiq In Leptomeningeal Metastases
18/08/2025 15:15
Aug 18 (Reuters) - Plus Therapeutics Inc PSTV.O: PLUS THERAPEUTICS PRESENTS POSITIVE RESPECT-LM CLINICAL TRIAL RESULTS OF REYOBIQ™ IN LEPTOMENINGEAL METASTASES PLUS THERAPEUTICS INC - NO DOSE LIMITING TOXICITIES OBSERVED IN TRIAL PLUS THERAPEUTICS INC - REYOBIQ SHOWS CLINICAL BENEFIT RATE OVER 75% Source text: ID:nGNX5hFC0c Further company coverage: PSTV.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cerenome
See all newsBrief: Cerenome Secures In-Network Agreement With Florida Blue For Cnside® Csf Tumor Cell Enumeration And Molecular Profile Tests
Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cerenome Secures In-Network Agreement With Health Care Service Corporation
Plus Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview
Brief: Plus Therapeutics Secures Regional Coverage Agreement With Medical Mutual For CNSide Cerebrospinal Fluid Assay For Metastatic CNS Cancer